Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

Total Live Articles: 381

Gonorrhoea

NICE CKS Gonorrhoea. Last revised Mar 2024.

BASHH Gonorrhoea 2025: Updated Guideline. Last updated Apr 2025.

Background Information

Aetiology

Gonorrhoea is an STI caused by the Gram -ve bacterium Neisseria gonorrhoea

Epidemiology

Gonorrhoea is the 2nd most common bacterial STI worldwide (after chlamydia).

Clinical Features

Genital Infection

Gonorrhoea is symptomatic in most men (>90%) and ~50% of women

Men
  • Purulent / mucopurulent urethral discharge (>80% cases)
  • Dysuria
  • Frequency and urgency are usually absent
Women
  • Dysuria without urinary frequency
  • Increased or altered vaginal discharge
  • Lower abdominal pain

Gonorrhoea rarely causes intermenstrual bleeding and menorrhagia (more commonly seen in chlamydia)

Extra-Genital Infection (Less Common)

Rectal gonorrhoea Usually asymptomatic

  • If symptomatic: anal discharge, pain or discomfort
  • Rectal infection in cisgender women is seen with and without a recent history of anal sex and is usually associated with urogenital infection
Gonococcal conjunctivitis Unilateral or bilateral red eye(s) with purulent, often hyper-purulent discharge

The bacteria can penetrate intact corneal epithelium – patients are at risk of rapidly progressive corneal ulceration and thinning, leading to possible perforation.

Oropharyngeal infection Usually asymptomaticIf symptomatic: pharyngitis and sore throat

Complications

Possible complications in men:

Possible complications in women:

  • PID (see the Pelvic Inflammatory Disease (PID))
  • Pregnancy complications
    • Miscarriage, premature labour, early rupture of fetal membranes
    • Perinatal mortality
    • Gonococcal conjunctivitis in the newborn

Disseminated gonorrhoea is a potentially serious complication that is thought to occur in 0.5–3% of untreated gonorrhoea cases.

  • Classic triad of 1) tenosynovitis 2) migratory polyarthralgia 3) dermatitis (petechial / pustular skin lesion)
  • Rarely endocarditis, or meningitis

Diagnosis

Gonorrhoea Testing

Test of choice: NAAT

Sample collection methods:

  • Male: first pass urine (alternative: urethral swab)
  • Female: vulvovaginal swab (alternative: endocervical swab or first pass urine)

If MSM → also take rectal and pharyngeal samples

Other tests:

Test Description
Culture Should be obtained simultaneously with NAAT and BEFORE starting treatment

For drug susceptibility testing

Urethral swab For quick diagnosis in the presence of penile urethral discharge

Interpretation:

  • Polymorphonuclear leukocytes + gram -ve diplococci → gonococcal urethritis
  • Polymorphonuclear leukocytes alone → non-gonococcal urethritis (NGU)

Management

Refer ALL patients to GUM clinic / local specialist for management.

General Advice

Abstain from all sexual activity until 7 days after they and their partner(s) have completed treatment

Pharmacological Management

Take swabs for culture BEFORE starting treatment, and initiate empirical treatment immediately without awaiting susceptibility result:

  • 1st line: ceftriaxone 1g IM single dose
  • 2nd line:
    • Needle-sparing option (e.g. if needle phobia) → cefixime 400mg PO (2 doses 6-12 hours apart) + azithromycin 2g PO
      • BASHH recommends only using this regimen if antimicrobial susceptibility results are available
    • Penicillin-sparing option → gentamicin 200mg IM + azithromycin 2g PO

Partner Notification and Sexual Contacts Management

Partner Notification

Partner notification period:

  • If symptomatic men → notify all partners within the past 2 weeks (or most recent partner if more than 2 weeks ago)
  • If all other patients (i.e. asymptomatic men and women) → notify all partners within the past 12 weeks (3 months)

The partner notification period for gonorrhoea is 1/2 that of chlamydia

In chlamydia:

  • Symptomatic men → 4 week lookback (vs 2 weeks in gonorrhoea)
  • All other patients (i.e. asymptomatic men and women) → 6-month lookback (vs 3 months in gonorrhoea)

Sexual Contacts Management

All sexual contacts should be tested:

  • Empirical treatment is NOT needed routinely for all sexual contacts:
  • Principle: only offer empirical treatment to those who test +ve for gonorrhoea
  • If present within 2 weeks of exposure → repeat testing after 2 weeks

Follow Up

Offer test of cure using NAAT to all patients at least 2 weeks after treatment completion

  • If treated with ceftriaxone + susceptible to ceftriaxone, there is no need for test of cure

At follow-up also check:

  • If symptoms resolved or not
  • Adherence
  • Any adverse reactions
  • Confirm partner notification has been carried out
  • Ask about recent sexual history
  • Reinforce advice on safe sexual practice

Note the window period of gonorrhoea testing is 2 weeks, meaning false -ve is possible if tested within this period. Therefore, the test of cure should be performed ≥2 weeks after completion of treatment.

References


Share Your Feedback Below

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Be first to accessour QBank

Sign up to receive major guideline updates and early access when we launch.